Insider Transactions in Q2 2024 at Precision Biosciences Inc (DTIL)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 10
2024
|
J. Jefferson Smith Chief Research Officer |
SELL
Open market or private sale
|
Direct |
50
-0.07%
|
$550
$11.79 P/Share
|
|
Jun 10
2024
|
Dario Scimeca General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
93
-1.36%
|
$1,023
$11.79 P/Share
|
|
Jun 07
2024
|
J. Jefferson Smith Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
163
+0.24%
|
-
|
|
Jun 07
2024
|
John Alexander Kelly Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
454
+1.42%
|
-
|
|
Jun 07
2024
|
Dario Scimeca General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
301
+4.23%
|
-
|
|
May 08
2024
|
Dario Scimeca General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
833
+11.34%
|
$9,996
$12.0 P/Share
|
|
May 08
2024
|
J. Jefferson Smith Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
833
+1.2%
|
$9,996
$12.0 P/Share
|
|
May 08
2024
|
John Alexander Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,334
+21.18%
|
$100,008
$12.0 P/Share
|
|
May 08
2024
|
Michael Amoroso President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,334
+27.38%
|
$100,008
$12.0 P/Share
|
|
May 04
2024
|
Melinda Brown |
BUY
Exercise of conversion of derivative security
|
Direct |
4,202
+50.0%
|
-
|
|
May 04
2024
|
Stanley Frankel |
BUY
Exercise of conversion of derivative security
|
Direct |
4,202
+49.7%
|
-
|
|
May 04
2024
|
Geno J Germano |
BUY
Exercise of conversion of derivative security
|
Direct |
4,202
+50.0%
|
-
|
|
May 04
2024
|
Samuel C. Wadsworth |
BUY
Exercise of conversion of derivative security
|
Direct |
4,202
+50.0%
|
-
|
|
May 04
2024
|
Kevin Buehler |
BUY
Exercise of conversion of derivative security
|
Direct |
4,202
+48.89%
|
-
|
|
May 04
2024
|
Shari Lisa Pire |
BUY
Exercise of conversion of derivative security
|
Direct |
4,202
+50.0%
|
-
|
|
May 02
2024
|
Michael Amoroso President and CEO |
SELL
Open market or private sale
|
Direct |
1,526
-9.98%
|
$15,260
$10.32 P/Share
|
|
May 02
2024
|
Alan List Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
290
-6.07%
|
$2,900
$10.32 P/Share
|
|
May 02
2024
|
J. Jefferson Smith Chief Research Officer |
SELL
Open market or private sale
|
Direct |
154
-0.23%
|
$1,540
$10.32 P/Share
|
|
May 02
2024
|
Dario Scimeca General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
272
-4.57%
|
$2,720
$10.32 P/Share
|
|
May 01
2024
|
John Alexander Kelly Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,702
+6.98%
|
-
|
|
May 01
2024
|
Michael Amoroso President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,417
+18.26%
|
-
|
|
May 01
2024
|
Alan List Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
982
+17.05%
|
-
|
|
May 01
2024
|
J. Jefferson Smith Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
519
+0.76%
|
-
|
|
May 01
2024
|
Dario Scimeca General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
918
+13.36%
|
-
|
|
Apr 30
2024
|
Alan List Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
238
-5.9%
|
$2,380
$10.03 P/Share
|
|
Apr 26
2024
|
Alan List Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
868
+17.71%
|
-
|